The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
Abstract
Objective: To examine the safety and efficacy of the interleukin‐1 (IL‐1) receptor antagonist anakinra as first‐line therapy for systemic juvenile idiopathic arthritis (JIA). Methods: Patients with systemic JIA receiving anakinra as part of initial disease‐modifying antirheumatic drug (DMARD) therapy were identified from 11 centers in 4 countries. Medical records were abstracted using a standardized instrument, and resulting data were analyzed to characterize concomitant therapies, clinical course, adverse events, and predictors of outcome. Results: Among 46 patients meeting inclusion criteria, anakinra monotherapy was used in 10 patients (22%), while 67% received corticosteroids and 33% received additional DMARDs. Outcomes were evaluated at a median followup interval of 14.5 months. Fever and rash resolved within 1 month in >95% of patients, while C‐reactive protein and ferritin normalized within this interval in >80% of patients. Active arthritis persisted at 1 month in 39% of patients, at 3 months in 27%, and at >6 months of followup in 11%. Approximately 60% of patients, including 8 of 10 receiving anakinra monotherapy, attained a complete response without escalation of therapy. Disease characteristics and treatment were similar in partial and complete responders, except that partial responders were markedly younger at onset (median age 5.2 years versus 10.2 years; P = 0.004). Associated adverse events included documented bacterial infection in 2 patients and hepatitis in 1 patient. Tachyphylaxis was not observed. Conclusion: Anakinra as first‐line therapy for systemic JIA was associated with rapid resolution of systemic symptoms and prevention of refractory arthritis in almost 90% of patients during the interval examined. These results justify further study of IL‐1 inhibition as first‐line, rather than rescue, therapy in systemic JIA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petty, R. E., Southwood, T. R. E., Manners, P. J., Baum, J., Glass, D. N., Goldenberg, J., He, X.-H., Maldonado-Cocco, J. A., Orozco-Alcalá, J., Prieur, A., et al. (2004) · PubMed · Cited by 4,176
THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS
STEINBROCKER, O. (1949) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1949.02900430001001 · Cited by 2,877
Preliminary definition of improvement in juvenile arthritis
Giannini, E. H., Ruperto, N., Ravelli, A., Lovell, D. J., Felson, D. T., & Martini, A. (1997) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199707)40:7<1202::aid-art3>3.0.co;2-r · Cited by 1,047
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.
Wallace, C. A., Ruperto, N., & Giannini, E. H. (2004) · PubMed · Cited by 735
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I., Michel, M., Dernis, E., Khellaf, M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076034 · Cited by 406
Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome
Packham, J. C. (2002) · Rheumatology · doi:10.1093/rheumatology/41.12.1428 · Cited by 385
Gattorno, M., Piccini, A., Lasigliè, D., Tassi, S., Brisca, G., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., Caroli, F., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23437 · Cited by 382
Cited by
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., Aricò, M., Avcin, T., Behrens, E. M., De Benedetti, F., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39332 · Cited by 773
Self-citationTwo Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 669
The Immunology of Macrophage Activation Syndrome
Crayne, C. B., Albeituni, S., Nichols, K. E., & Cron, R. Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00119 · Cited by 633
Self-citationSota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01526 · Cited by 616
Self-citationTreating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., & Sève, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.058 · Cited by 518
Macrophage activation syndrome in the era of biologic therapy
Grom, A. A., Horne, A., & De Benedetti, F. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.179 · Cited by 448
Minoia, F., Davì, S., Horne, A., Demirkaya, E., Bovis, F., Li, C., Lehmberg, K., Weitzman, S., Insalaco, A., Wouters, C., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38802 · Cited by 429
Self-citationJuvenile Idiopathic Arthritis: Will Etanercept be an Improvement over Current Therapies?
De Benedetti, F., & Ravelli, A. (2000) · BioDrugs · doi:10.2165/00063030-200014020-00003 · Cited by 428
Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., Aricò, M., Avcin, T., Behrens, E. M., De Benedetti, F., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208982 · Cited by 410
Self-citationPathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Schulert, G. S., & Grom, A. A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 402
Weiss, E. S., Girard-Guyonvarc’h, C., Holzinger, D., de Jesus, A. A., Tariq, Z., Picarsic, J., Schiffrin, E. J., Foell, D., Grom, A. A., Ammann, S., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820852 · Cited by 395
Ravelli, A., Grom, A. A., Behrens, E. M., & Cron, R. Q. (2012) · Genes & Immunity · doi:10.1038/gene.2012.3 · Cited by 386
Self-citationPathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions
Mellins, E. D., Macaubas, C., & Grom, A. A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.68 · Cited by 330
Ringold, S., Weiss, P. F., Beukelman, T., DeWitt, E. M., Ilowite, N. T., Kimura, Y., Laxer, R. M., Lovell, D. J., Nigrovic, P. A., Robinson, A. B., et al. (2013) · Arthritis Care & Research · doi:10.1002/acr.22087 · Cited by 306
Self-citationReview: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
Webb, B. J., Peltan, I. D., Jensen, P., Hoda, D., Hunter, B., Silver, A., Starr, N., Buckel, W., Grisel, N., Hummel, E., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30343-x · Cited by 293
Martini, A., Lovell, D. J., Albani, S., Brunner, H. I., Hyrich, K. L., Thompson, S. D., & Ruperto, N. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00332-8 · Cited by 289
Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J., & Tattersall, R. S. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30096-5 · Cited by 285
Self-citationCarter, S. J., Tattersall, R. S., & Ramanan, A. V. (2019) · Rheumatology · doi:10.1093/rheumatology/key006 · Cited by 259
Vastert, S. J., de Jager, W., Noordman, B. J., Holzinger, D., Kuis, W., Prakken, B. J., & Wulffraat, N. M. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38296 · Cited by 258
Wong, S. C., Dobie, R., Altowati, M. A., Werther, G. A., Farquharson, C., & Ahmed, S. F. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1026 · Cited by 163
Pardeo, M., Bracaglia, C., & De Benedetti, F. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.02.002 · Cited by 60
Self-citation
Metadata
- Authors
- Nigrovic, P. A., Mannion, M., Prince, F. H. M., Zeft, A., Rabinovich, C. E., van Rossum, M. A. J., Cortis, E., Pardeo, M., Miettunen, P. M., Janow, G., Birmingham, J., Eggebeen, A., Janssen, E., Shulman, A. I., Son, M. B., Hong, S., Jones, K., Ilowite, N. T., Cron, R. Q., & Higgins, G. C.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2011-01-28
- Volume
- 63
- Issue
- 2
- Pages
- 545-555
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2026404803
- Cited by
- 463
- References
- 31
- FWCI
- 19.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.